0 companies available
↑ ↓ to navigate Enter to select Esc to close
JOHNSON & JOHNSON
JNJ
Pharmaceutical Preparations Last filing · Quarter 2 · Jun 28, 2026Export XLSX
Format
% Change
Rows
| USD ($) $ in Millions, shares in Millions | LTM | Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Jan 1, 2023 | Jan 2, 2022 | Jan 3, 2021 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Jan 1, 2017 | Jan 3, 2016 | Dec 28, 2014 | Dec 29, 2013 | Dec 30, 2012 | Jan 1, 2012 | Jan 2, 2011 | Jan 3, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales to customers | $ 97,929 | $ 94,193 | $ 88,821 | $ 85,159 | ||||||||||||||
Cost of products sold | 31,428 | 30,256 | 27,471 | 26,553 | ||||||||||||||
Gross profit | 66,501 | 63,937 | 61,350 | 58,606 | ||||||||||||||
Selling, marketing and administrative expenses | 25,141 | 23,676 | 22,869 | 21,512 | ||||||||||||||
Research and development expense | 15,104 | 14,665 | 17,232 | 15,085 | ||||||||||||||
In-process research and development impairments | 117 | 81 | 211 | 313 | ||||||||||||||
Interest income | 912 | 1,056 | 1,332 | 1,261 | ||||||||||||||
Interest expense, net of portion capitalized | (1,012) | (971) | (755) | (772) | ||||||||||||||
Other (income) expense, net | (630) | 7,209 | (4,694) | (6,634) | ||||||||||||||
Restructuring | 213 | 228 | 234 | 489 | ||||||||||||||
Earnings before provision for taxes on income | 25,196 | 32,581 | 16,687 | 15,062 | ||||||||||||||
Effective Rate | 4,159 | 5,777 | 2,621 | 1,736 | ||||||||||||||
Net earnings from continuing operations | 26,804 | 26,804 | 14,066 | 13,326 | ||||||||||||||
Net earnings from discontinued operations | 0 | 0 | 0 | 21,827 | ||||||||||||||
Net earnings | - | - | - | - | ||||||||||||||
Add: Net loss attributable to noncontrolling interest | - | - | - | - | ||||||||||||||
Net earnings | $ 21,037 | $ 26,804 | $ 14,066 | $ 35,153 | ||||||||||||||
Net earnings per share | ||||||||||||||||||
Basic net earnings per share from continuing operations (in dollars per share) | $ 11.13 | $ 11.13 | $ 5.84 | $ 5.26 | ||||||||||||||
Basic net earnings per share from discontinued operations (in dollars per share) | 0 | 0 | 0 | 8.62 | ||||||||||||||
Basic (in dollars per share) | 8.73 | 11.13 | 5.84 | 13.88 | ||||||||||||||
Diluted net earnings per share from continuing operations (in dollars per share) | 11.03 | 11.03 | 5.79 | 5.2 | ||||||||||||||
Diluted net earnings per share from discontinuing operations (in dollars per share) | 0 | 0 | 0 | 8.52 | ||||||||||||||
Diluted (in dollars per share) | 8.62 | 11.03 | 5.79 | 13.72 | ||||||||||||||
Cash dividends per share (in dollars per share) | - | - | - | - | ||||||||||||||
Average shares outstanding | ||||||||||||||||||
Basic (in shares) | 2,408.1 | 2,407.4 | 2,407.3 | 2,533.5 | ||||||||||||||
Diluted (in shares) | 2,443.9 | 2,429.4 | 2,429.4 | 2,560.4 |